Documente Academic
Documente Profesional
Documente Cultură
P 0.0112.
P 0.001.
Table 2 Utility value fains according to Psoriasis Area
and Severity Index (PASI) level.
PASI response category Utility gains for all patients
PHOENIX
calculation*
TA 146
calculation
50 0.0400 0.063
5 0 and 75 0.1700 0.1780
75 and 90 0.2200 0.1780
90 0.2500 0.3080
* Calculated from PHOENIX 1 and 2 using regression presented in
Woolacott et al. [8].
Outpatient visits
Total
Costs for initial trial period (12 wks)
Etanercept 50 mg (biweekly) $9,404.88 $55.86 $61.20 $9,521.94
Ustekinumab 45 mg (0,4 wks) $8,400.00 $55.86 $61.20 $8,517.06
Costs for maintenance treatment period
Etanercept 50 mg weekly $20,447.22 $55.86 $81.60 $20,584.68
Ustekinumab 45 mg q 12 wks $18,262.50 $55.86 $81.60 $18,399.96
Palliative care $123.60 $123.60
* All costs are in the Canadian dollar.
($2,718) 0.0153
QALY, Quality-adjusted life years; NICE, National Institute for Clinical Excellence.
* All costs are in the Canadian dollar.
See Table 2 for utility gain according to PASI response level; ( ) indicates negative number.
Fig. 2 Scatter plot of probabalistic analysis of incremental
difference in costs and quality-adjusted life years (QALYs)
between ustekinumab and etanercept.
655 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 2 6 5 6
helps to narrow differences and potentially makes the ndings
more useful for decision makers.
Because the ACCEPT trial included approximately 48%patients
from Canada, its outcomes are expected to be representative of
refractory moderate-to-severe psoriasis patients in the general
Canadian population. Although there are a number of therapies
usedto treat moderate-to-severe psoriasis inCanada, biologics are
recommended and used when patients have failed, are intolerant
or have contraindicated to systemic therapies or phototherapy
(e.g., ultraviolet B rays). The ACCEPT trial focused on refractory
patients who had experienced conventional therapies, and com-
pared ustekinumab to etanerceptthe most used and recom-
mended biologic in Canada. Therefore, from the perspective of
Canadian reimbursement authorities, etanercept was the most
appropriate comparator for the cost-effective analysis. Data from
the 12-week head-to-head trial were used in the model with the as-
sumptionthat the response wouldbe maintainedover the long-term
for both ustekinumab and etanercept if patients remained on the
treatment. Inthe case of ustekinumab, this assumptionis supported
by analyses of 1 and 1.5 years duration of data from PHOENIX 1 and
PHOENIX 2 [2,3] demonstrating sustained efcacy with mainte-
nance dosing. Intermittent dosing for psoriasis management has
been considered in some jurisdictions, but the Canadian regula-
tory authority has recommended maintenance dosing for usteki-
numab (45 mg administeredevery 12 weeks) andfor etanercept (50
mg every week). Moreover, two published randomized controlled
trials show that continuous use of etanercept is clinically superior
to intermittent use of etanercept [12,13]. Thus, continuous dosing
was used in our economic analysis.
Although the results and sensitivity analyses indicate robust-
ness of the conclusions, there are limitations that warrant discus-
sion. The ACCEPT trial did not collect resource use data nor were
there any Canadian databases to elicit information on the re-
sources utilized by psoriasis patients. This cost utility study relied
only upon expert clinical opinion supported by a recent Canadian
survey of ninety moderate to severe psoriasis patients reporting
their resource use [9].
Second, the regression equation upon which the relationship
between DLQI and EQ-5D utility values is based on was derived
using data from a UK population and assumed a linear relation-
ship between the two scores. It is not known whether the values
are transferable or appropriate to the Canadian population. Also
the linearity between the DLQI and EQ-5D scores has not been
validated. The utility values, however, are conservatively applied
across both therapies resulting in a small difference in favour of
ustekinumabduetothehigher percentageof patients achievingPASI
75 response. Third, the rate of patient discontinuation in ACCEPT
was similar tothat usedinthepreviouslydescribedHTAreports [7,8].
Regardless, our cost utility analysis employed a 20% rate of discon-
tinuation equally across both therapies.
This model highlights the great advantage of having head-to-
head comparative trial data relevant to the at-risk population. It
offers an approach to adopt similar assumptions from other mod-
els within the disease area, making it easier for health authorities
and payers to interpret the ndings.
Conclusions
The present model indicates that ustekinumab is more cost-effec-
tive than etanercept for patients with moderate-to-severe plaque
psoriasis.
Source of nancial support: Provided by Janssen Inc.
R E F E R E N C E S
[1] Grifths CE, Strober BE, van de Kerkhof P, et al. Comparison of
ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl
J Med 2010;14;362:11828.
[2] Leonardi CL, Kimball AB, Papp KA, et al. Efcacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in
patients with psoriasis: 76-week results from a randomised, double-
blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:166574.
[3] Papp KA, Langley RG, Lebwohl M, et al. Efcacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal antibody, in
patients with psoriasis: 52-week results from a randomised, double-
blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:167584.
[4] Langley RG, Feldman SR, Han C, et al. Ustekinumab signicantly
improves symptoms of anxiety, depression, and skin-related quality
of life in patients with moderate-to-severe psoriasis: results from a
randomized, double-blind, placebo-controlled phase III trial. J Am
Acad Dermatol 2010;63:45765.
[5] Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-
related quality of life in patients with moderate-to-severe psoriasis:
results from the PHOENIX 1 trial. Br J Dermatol 2010;162:13746.
[6] Guidelines for the economic evaluation of health technologies:
Canada, 3rd ed. Available from: http://www.cadth.ca/media/pdf/
186_EconomicGuidelines_e.pdf. [Accesssed October 16, 2009].
[7] NICE technology appraisal guidance 146. Adalimumab for the
treatment of adults with psoriasis. National Institute for Health and
Clinical Excellence, London, UK 2008; Available from: http://www.
nice.org.uk/TA146 [Accessed on October 16, 2009].
[8] Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab
for the treatment of psoriasis: a systematic review. Health Technol
Assess 2006;10:1iv.
[9] Davie A, Brazier N, Tsao N, et al. Economic burden of moderate to
severe chronic plaque psoriasis in Canada. ISPOR 14th Annual
International Meeting, May 1620, 2009, Orlando, Florida.
[10] Ontario Health Insurance Plan. Schedule of Benets Physician
Services. Ontario: Ministry of Health and Long Term Care,
Government of Ontario, Canada; 2009.
[11] Ontario Health Insurance Plan. Schedule of Benets for Laboratory
Services. Ontario: Ministry of Health and Long Term Care,
Government of Ontario, Canada; 1999.
[12] Moore A, Gordon KB, Kang S, et al. A randomized, open-labeled trial of
continuous versus interrupted etanercept therapy in the treatment of
psoriasis. J Am Acad Dermatol 2007;56:598602.
[13] Ortonne JP, Grifths C, Dadn E, et al. Efcacy and safety of
continuous versus paused etanercept treatment in patients with
moderate to severe psoriasis over 52 weeks: the CRYSTEL study.
Expert Rev Dermatol 2008;3:65765.
656 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 2 6 5 6